该研究结果支持在其他AML患者人群中进一步探索CPX-351联合维奈克拉方案的运用。 【参考文献】 Uy GL, Pullarkat V, Baratam P, et al. Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapy. Blood Adv. 2024 Dec 24;8(24):6248-6256. doi...
Lancet JE, Uy GL, Newell LF, et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia:5-year results of a randomised, open-...
CPX-351 was approved by the Food and Drug Administration (FDA) in 2017 as an induction chemotherapy regimen for patients with AML-MRC or t-AML as defined by 2016 World Health Organization (WHO) classification. A large randomized phase 3 study that led to approval of CPX-351 included only ...
Journal of Hematology & Oncology (2022) 15:155 https://doi.org/10.1186/s13045-022-01361-w BRIEF REPORT Open Access Efficacy and safety of CPX‑351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high‑risk/...
putting them through induction chemotherapy, and proceeding to a stem cell transplant. Certainly, we want to know that those patients post-transplant are going to continue to do well, and that the relapse rate post-transplant and the survival post-transplant are hopefully improved for patients with...
CPX-351 is a liposomal formulation of cytarabine/daunorubicin with a 5:1 fixed molar ratio. We investigated the safety and efficacy of escalating doses of CPX-351 in patients with acute myeloid leukemia (AML) at high risk of induction mortality with standard chemotherapy determined through ...
For CR alone, the rates were 37.3% and 25.6%, between CPX-351 and 7+3, respectively (P = .04). Patients who achieved a CR or CRi were eligible to receive consolidation chemotherapy. In the investigation arm, consolidation CPX-351 was administered at 65 u/m2 on days 1 and 3. In ...
More patients with acute myeloid leukemia could proceed to transplant following treatment with CPX-351 compared with the traditional 7+3 chemotherapy regimen. Jeffrey E. Lancet, MD More patients with acute myeloid leukemia (AML) could proceed to transplant following treatment with CPX-351 (Vyxeos) ...
CPX-351expanded access programCPX-351, a dual-drug liposomal encapsulation of cytarabine and daunorubicin at a synergistic 5:1 molar drug ratio, achieved superior efficacy compared with conventional chemotherapy in older adults with newly diagnosed, high-risk/secondary acute myeloid leukemia (AML) in ...
A new liposomal formulation of chemotherapy agents has produced such promising results in a phase 3 clinical trial that experts say it should become a standard of care in the treatment of acute myeloid leukemia (AML), even though it is not yet approved. The product, CPX-351 (Vyxeos, Celator...